What is the primary medical therapy for a patient with symptomatic mitral stenosis?

Medical Therapy for Symptomatic Mitral Stenosis

Medical therapy for symptomatic mitral stenosis is purely palliative and does not prevent disease progression—the definitive treatment is intervention with percutaneous mitral commissurotomy (PMC) or surgery. 1, 2 However, while awaiting intervention or in patients who are not candidates for mechanical relief, specific medical therapies can provide symptom relief and prevent complications.

Symptom Management

Diuretics are the cornerstone for relieving pulmonary congestion and peripheral edema in symptomatic patients with mitral stenosis. 1, 2 These medications reduce preload and alleviate dyspnea and orthopnea by decreasing pulmonary venous pressure.

Heart rate control is critical, particularly in patients with atrial fibrillation, as slower heart rates prolong diastolic filling time across the stenotic valve. 1, 2 The following agents are recommended:

• Beta-blockers (e.g., metoprolol, atenolol) are first-line for rate control 1, 2
• Non-dihydropyridine calcium channel blockers (e.g., diltiazem, verapamil) are effective alternatives 1, 2
• Digoxin is specifically recommended for heart rate control in patients with atrial fibrillation and mitral stenosis 1, 2

Anticoagulation Therapy

Anticoagulation with vitamin K antagonists (warfarin) is mandatory in specific high-risk situations, targeting an INR of 2.0-3.0. 2, 3 The indications include:

• Atrial fibrillation (paroxysmal or persistent) 1, 2, 3
• History of systemic embolism 1, 4
• Dense spontaneous contrast in the left atrium on echocardiography 1, 4
• Enlarged left atrium (M-mode diameter >60 mL/m²) 1
• Left atrial thrombus 4

Critical Caveat on Anticoagulation

Patients with mitral stenosis and atrial fibrillation should receive vitamin K antagonists (warfarin) and NOT direct oral anticoagulants (DOACs). 1 While one retrospective Korean study suggested potential benefit of DOACs in this population 5, all major randomized trials of DOACs specifically excluded patients with moderate-to-severe mitral stenosis, and current guidelines do not support their use. 1 The FDA label for warfarin explicitly includes mitral stenosis as an indication. 3

When Medical Therapy Alone Is Insufficient

Medical therapy should be viewed as a bridge to intervention, not a long-term solution. 1, 2 The following scenarios mandate urgent cardiology referral for intervention:

• Symptomatic patients (NYHA class II-IV) with dyspnea, fatigue, or pulmonary congestion and valve area <1.5 cm² require intervention 6, 4
• Pulmonary artery systolic pressure >50 mmHg at rest, even if asymptomatic 6, 4, 2
• New-onset atrial fibrillation 6, 4, 2
• Desire for pregnancy in women with severe mitral stenosis 4, 2
• Need for major non-cardiac surgery 4

Monitoring Strategy

Regular follow-up is essential to detect progression and identify indications for intervention:

• Asymptomatic severe mitral stenosis (MVA ≤1.0 cm²): Follow-up every 2-3 years per European Society of Cardiology 1, 2 or every 3-5 years per American College of Cardiology/American Heart Association 1
• Symptomatic patients on medical therapy: More frequent monitoring with clinical assessment and echocardiography 1

Common Pitfalls to Avoid

The most dangerous pitfall is treating symptomatic severe mitral stenosis with medical therapy alone for extended periods. 1, 2 This approach allows irreversible pulmonary hypertension, right heart failure, and increased mortality risk. 4 Delays in referral for mechanical intervention can lead to progression beyond the point where PMC is feasible, necessitating higher-risk valve replacement surgery.

Another critical error is using DOACs instead of warfarin in patients with mitral stenosis and atrial fibrillation. 1 Despite the convenience of DOACs, they lack evidence in this population and are not guideline-recommended.

Failure to exclude left atrial thrombus before PMC is a serious oversight—transesophageal echocardiography (TOE) must be performed before any intervention. 6 If thrombus is present in the left atrial appendage, 1-3 months of anticoagulation with repeat TOE is required before proceeding. 6